Viking Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$35.52(as of Apr 14, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Viking Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$35.52
Ticker SymbolVKTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees53
CountyUSA
Market Cap$4,057.4M
EBIDTAUnknown
10-Day Moving Average34.13
P/E Ratio-11.26
20-Day Moving Average33.56
Forward P/E Ratio0.00
50-Day Moving Average32.50
Earnings per Share-3.19
200-Day Moving Average32.50
Profit Margin-Infinity%
RSI57.70
Shares Outstanding115.9M
ATR1.87
52-Week High43.15
Volume2,142,282
52-Week Low21.23
Most Recent Support Level33.78
Book Value639.1M
Most Recent Resistance Level35.24
P/B Ratio6.34
Upper Keltner37.76
P/S RatioInfinity
Lower Keltner29.37
Debt-to-Equity Ratio37.76
Next Earnings Date04/29/2026
Cash Surplus89.1M
Next Ex-Dividend DateUnknown

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics Inc In Our Stock Scanner

As of Apr 15, 2026
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.